Mechanism of Stimulation of Osteoclastic Bone Resorption through Gas6/Tyro 3, a Receptor Tyrosine Kinase Signaling, in Mouse Osteoclasts*

Mika KatagiriDagger §, Yoshiyuki Hakeda, Daichi ChikazuDagger §, Toru OgasawaraDagger §, Tsuyoshi Takato§, Masayoshi Kumegawa, Kozo NakamuraDagger , and Hiroshi KawaguchiDagger ||

From the Departments of Dagger  Orthopaedic Surgery and § Oral and Maxillofacial Surgery, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-8655 and the  Department of Oral Anatomy, School of Dentistry, Meikai University, Sakado, Saitama 350-0248, Japan

Received for publication, August 14, 2000, and in revised form, November 13, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The signaling through receptor tyrosine kinases expressed on mature osteoclasts has recently been suggested to be involved in osteoclastic bone resorption. This study investigated the mechanism and the possible physiological relevance of Gas6/Tyro 3, a receptor tyrosine kinase signaling pathway in osteoclasts in stimulating osteoclastic bone resorption using several mouse culture systems. Gas6, expressed ubiquitously in bone cells, did not affect the differentiation or the survival of osteoclasts, but stimulated osteoclast function to form resorbed pits on a dentine slice. The expression of its receptor, Tyro 3, was seen only in mature osteoclasts among bone cells. Gas6 up-regulated the phosphorylation of cellular proteins including p42/p44 mitogen-activated protein kinase (MAPK), but not p38 or c-Jun N-terminal kinase MAPK, and increased the kinase activity of immunoprecipitated Tyro 3 in isolated osteoclasts. The ability of Gas6 to stimulate pit formation resorbed by osteoclasts was abrogated by PD98059, a specific inhibitor of p42/p44 MAPK. In addition, the Gas6 mRNA level in bone marrow was up-regulated by ovariectomy and was reduced by estrogen replacement. These results strongly suggest that Gas6 acts directly on mature osteoclasts through activation of Tyro 3 and p42/p44 MAPK, possibly contributing to the bone loss by estrogen deficiency.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Osteoclastic bone resorption is regulated by the differentiation, function, and survival of osteoclasts. The tumor necrosis factor family molecule receptor activator of nuclear factor (NF)1-kappa B ligand/osteoclast differentiation factor (RANKL/ODF) was identified as the membrane-associated molecule regulating osteoclast differentiation (1-3); however, the signaling pathways in regulating mature osteoclast function and survival are still controversial. Recent study of random sequence analysis of PCR-amplified cDNA clones identified 14 distinct kinase-related genes in purified rabbit mature osteoclasts, and 8 of them were identified as receptor tyrosine kinases (RTKs) (4). RTKs expressed on mature osteoclasts include fibroblast growth factor receptor type 1 (FGFR1), c-Fms, and Tyro 3, whose ligands: FGF-2, macrophage-colony stimulating factor (M-CSF), and the growth arrest-specific gene 6 (Gas6), respectively, are known to regulate osteoclast differentiation, function, or survival. We recently reported that FGF-2 stimulates mature osteoclast function directly through the activation of FGFR1 on mature osteoclasts (5, 6). M-CSF is also reported to stimulate the survival and chemotactic behavior of osteoclasts through the activation of its receptor, c-Fms, on osteoclasts (7-10). Another RTK, Tyro 3, is the RTK most frequently cloned in isolated rabbit osteoclasts in the random sequence study above (4). Tyro 3, also known as Sky, Rse, Brt, and Tif, is a member of the Axl, Ufo, and Sky family RTKs (11-14) containing characteristic extracellular ligand binding domain composed of two immunoglobulin-like domains and two fibronectin type III repeats (15, 16). The ligand for Tyro 3 is known to be Gas6, which is a vitamin K-dependent protein acting as a growth-potentiating factor for thrombin-induced cell proliferation (17-19).

We now propose the possibility that signaling through RTKs on osteoclasts contributes not only to osteoclastic function but also to the pathophysiology of osteopenic disorders. In this regard, we recently reported that endogenous FGF-2 in the synovial fluid contributes to joint destruction in rheumatoid arthritis (RA) patients through a direct action on mature osteoclasts (5, 6, 20). M-CSF has been implicated in the pathophysiology of the bone loss of ovariectomy (21-24). Hence, in this study we examined the mechanism whereby Gas6/Tyro 3 signaling stimulates osteoclastic bone resorption using several mouse culture systems, and investigated the possible physiological relevance of this signaling to the bone loss of estrogen deficiency.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Neonatal, 5-week-old, and 8-week-old ddY mice were purchased from Shizuoka Laboratories Animal Center (Shizuoka, Japan). Rat recombinant Gas6 and human recombinant FGF-2 were generously provided by Shionogi Research Laboratory (Osaka, Japan) and Kaken Pharmaceutical Co., Ltd. (Kyoto, Japan), respectively. alpha -Modified minimum essential medium (alpha MEM) was purchased from Life Technologies, Inc., and fetal bovine serum (FBS) was from the Cell Culture Laboratory (Cleveland, OH). Recombinant human M-CSF was purchased from R&D Systems Inc. (Minneapolis, MN). Recombinant human soluble RANKL/ODF was purchased from PeproTech, Inc. (London, United Kingdom (UK)). Bacterial collagenase, 1,25(OH)2 vitamin D3, and ISOGEN were purchased from Wako Pure Chemicals Co. (Osaka, Japan), and dispase from Nitta Gelatin Co. (Osaka). Monoclonal mouse antibody against phosphotyrosine was obtained from Upstate Biotechnology Inc. (Lake Placid, NY), and monoclonal mouse antibody against p60v-src (mAb 327) from Oncogene Research Products (Cambridge, MA). This antibody recognizes specifically both p60v-src and p60c-src, and has been used to determine the expression of p60c-src in various primary cells and clonal cell lines. Polyclonal goat antibody against mouse Tyro 3 and nonimmune IgG as well as blocking peptides for respective antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). [32P]dCTP and [gamma -32P]ATP were obtained from Amersham Pharmacia Biotech (Buckinghamshire, UK). Herbimycin A and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1) were from Alexis Biochemicals (San Diego, CA). 2'-Amino-3'-methoxyflanone (PD98059), monoclonal mouse antibody against phospho-p44/42 MAPK, polyclonal rabbit antibody against phospho-p38 MAPK, and mouse monoclonal against phospho-JNK MAPK, were obtained from New England Biolabs, Inc. (Beverly, MA). 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580) was purchased from Calbiochem-Novobiochem Co. (La Jolla, CA). Other chemicals were obtained from Sigma.

Mouse Primary Osteoblast Culture-- All animal experiments were performed according to the guidelines of the International Association for the Study of Pain (25). In addition, the experimental work was reviewed by the committee of Tokyo University charged with confirming ethics. Calvariae dissected from 1-4-day-old mice were washed in phosphate-buffered saline (PBS) and digested with 1 ml of trypsin/EDTA (Life Technologies, Inc.) containing 10 mg of collagenase (Sigma, type 7) for 10 min five times, and cells from fractions 3-5 were pooled. Cells were plated in six-multiwell dishes at a density of 5,000 cells/cm2 and grown to confluence in alpha MEM containing 10% FBS.

Resorbed Pit Formation Assay in the Coculture of Mouse Bone Marrow Cells and Osteoblasts-- Mouse osteoblasts (1 × 106 cells/dish) prepared as described above and bone marrow cells (2 × 107 cells/dish) from tibiae of 8-week-old ddY mice were cocultured on 10-cm culture dishes coated with 0.24% collagen gel matrix (Nitta Gelatin, Tokyo, Japan) containing alpha MEM with 10% FBS, 1,25(OH)2 vitamin D3 (10-8 M), and PGE2 (10-6 M) for 6 days with a medium change every 3 days, and for 1 additional day in alpha MEM with 10% FBS. After culture for 7 days, non adherent cells were washed with PBS and adherent cells were stripped by 0.2% bacterial collagenase. An aliquot of crude osteoclast preparation (0.1 ml) was further cultured on a dentine slice placed in each well of 96-well dishes containing alpha MEM and 10% FBS in the presence or absence of Gas6 (10-14 to 10-8 M) and/or PD98059 (1-30 µM) and SB203580 (30 µM). After 48 h of culture, cells were removed with 1 N NH4OH solution, and stained with 0.5% toluidine blue. Total area was estimated under a light microscope with a micrometer to assess osteoclastic bone resorption using an image analyzer (System Supply Co., Nagano, Japan). At the same time, cells on a dentine slice in the independent culture were fixed with 3.7% (v/v) formaldehyde in PBS and ethanol-acetone (50:50, v/v), and stained at pH 5.0 in the presence of L(+)-tartaric acid using naphthol AS-MX phosphate (Sigma) in N,N-dimethyl formamide as the substrate. Tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells containing more than three nuclei were counted as osteoclasts.

TRAP-positive Multinucleated Cell Formation Assay in the Mouse Coculture System-- Mouse osteoblasts (3 × 104 cells/well) and bone marrow cells (1 × 106 cells/well) were cocultured in 24-multiwell dishes containing alpha MEM and 10% FBS in the presence and/or absence of Gas6 (10-14 to 10-8 M) for 6 days with a medium change at 3 days. After 6 days of culture, the cells were fixed and stained for TRAP as described above. TRAP-positive multinucleated cells containing more than three nuclei were counted as osteoclasts.

Analysis of Osteoclast Survival-- Coculture of mouse osteoblasts and marrow cells was performed on 10-cm culture dishes coated with 0.24% collagen gel matrix to obtain osteoclasts as described above. After 7 days of culture, dishes were treated with 4 ml of 0.2% bacterial collagenase in alpha MEM for 20 min at 37 °C, and collected cells were suspended in 170 ml of alpha MEM and 10% FBS. An aliquot of crude osteoclast preparation (2 ml) was replaced in 12-well dishes, and further cultured. After incubation for 2 h, the plates were treated with PBS containing 0.001% Pronase E and 0.02% EDTA to remove stromal cells. After purification, osteoclasts were cultured in the presence or absence of Gas6 (10-8 M) or M-CSF (100 ng/ml) for various periods up to 72 h, stained with trypan blue and TRAP. Trypan blue-negative and TRAP-positive cells were counted as living osteoclasts.

Reverse Transcriptase-PCR (RT-PCR) for Gas6 and Tyro 3-- Mouse osteoblasts and marrow cells were cocultured in 10-cm dishes as described above. After 6 days of culture, osteoclasts were formed and isolated by 0.001% Pronase E and 0.02% EDTA in PBS. In addition, to obtain osteoclastic cells in various differentiation stages, spleen cells (2 × 108 cells/dish) from 8-week-old mice were cultured on 10-cm culture dishes containing alpha MEM and 10% FBS with soluble RANKL/ODF (100 ng/ml) and M-CSF (10 ng/ml) for 6 days. Total RNA was extracted from mouse brain, bone marrow cells, osteoblasts, osteoclasts, and cultured spleen cells harvested every day using ISOGEN following the manufacturer's instructions, and 2 µg of RNA was reverse-transcribed and amplified by PCR using Ampli-Taq Gold (PerkinElmer Life Sciences). The primers for Gas6 were sense (5'-CCATCAACCACGGCATGTGG-3') and antisense (5'-TCGCACACCTTGATTTCCAT-3') and for Tyro 3 were sense (5'-GGAAGAGACGCAAGGAGAC-3') and antisense (5'-ATGGGAATGGGGAGACGAC-3'). The cycling parameters were 1 min at 96 °C, 30 s at 58 °C, 1 min 30 s at 72 °C for 25 cycles. The PCR products for Gas6 and Tyro 3 were 589 and 445 base pairs, respectively.

Western Blot Analysis for Tyro 3-- Mouse osteoclasts and osteoblasts were lysed with TNE buffer (10 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 10 mM NaF, 2 mM Na3VO4, 1 mM aminoethylbenzenesulfonyl fluoride, and 10 µg/ml aprotinin). The protein concentration in the cell lysate was measured using a Protein Assay Kit II (Bio-Rad). Equivalent amounts (60 µg) of cell lysates were electrophoresed by 8% SDS-PAGE and transferred to nitrocellulose membrane. After blocking nonspecific binding with 5% skim milk, Tyro 3-containing proteins were stained using the ECL chemiluminescence reaction (Amersham Pharmacia Biotech) following the manufacture's instructions. After this visualization, the antibodies on the membrane were stripped in a buffer consisting of 62.5 mM Tris-HCl (pH 6.7), 2% SDS, and 100 mM 2-mercaptoethanol at 50 °C for 40 min. To ascertain the specificity of these blottings, the stripping membrane was further immunoreacted with polyclonal anti-Tyro 3 and respective blocking peptide, and the immunoreactive bands were again visualized under the above conditions. The immunoreactivity to anti-Tyro 3 was not lost by this stripping procedure.

Assay for Tyrosine Phosphorylation of Cellular Proteins-- Isolated mouse osteoclasts were incubated in alpha MEM, 0.1% FBS for 2 h and treated with Gas6 (5 × 10-9 M) for various periods (0-10 min). Cell lysates containing equal amounts of protein (20 µg) were analyzed by Western blot as described above. After blocking with 5% bovine serum albumin, the membrane was incubated with monoclonal mouse antibody against phosphotyrosine and with peroxidase-conjugated anti-mouse IgG antibody. Phosphotyrosine-containing proteins were visualized using the ECL chemiluminescence reaction following the manufacturer's instructions. After the antibody was stripped from the membrane, membranes were incubated with 5% skim milk to block nonspecific binding, and then with monoclonal mouse antibody against p60v-src, monoclonal mouse antibodies against phospho-p44/42 MAPK, -JNK MAPK, polyclonal rabbit antibodies against phospho-p38 MAPK, and the immunoreactive bands were visualized as described above.

In Vitro Kinase Assay-- Equal amounts of protein (100 µg) from osteoclasts stimulated with Gas6 for various periods were immunoprecipitated with 1 µg of polyclonal goat antibody against mouse Tyro 3 for 4 h at 4 °C, and the immune complexes were recovered with protein G-Sepharose (Life Technologies, Inc.). The immune complex was washed three times with TNE buffer and three times with kinase buffer (20 mM HEPES-NaOH (pH 7.4), and 10 mM MgCl2); the samples were then resuspended in 60 µl of kinase buffer with 1 µCi (37 kBq) of [gamma -32P]ATP, and incubated for 15 min at 30 °C. The reaction was stopped by adding 20 µl of 4× sample buffer (250 mM Tris-HCl (pH 6.8), 8 mM EDTA, 12% SDS, 500 mM 2-mercaptoethanol, 15% glycerol, and 0.01% bromphenol blue) and subjected to 10% SDS-PAGE under reducing conditions followed by autoradiography.

Northern Blotting for Bone and Bone Marrow Cells of Sham-operated, Ovariectomized (OVX), and Estrogen-replaced OVX Mice-- Eight-week-old female ddY mice were subjected to either dorsal ovariectomy or sham operation under general anesthesia. The OVX mice were implanted with either a placebo pellet (n = 6) or a slow release (21 days) pellet containing 10 µg of 17beta -estradiol (Innovative Research of America, Toledo, OH) (n = 6). The sham-operated mice were also implanted with a placebo pellet (n = 6). Mice were sacrificed 3 weeks after surgery, and the whole tibiae and femora were excised. To extract RNA from cells of bone marrow cells and residual bone from which bone marrow was removed, epiphyses at both ends were cut off, bone marrow was flushed with PBS, collected cells were suspended in ISOGEN extraction buffer, and total RNA was extracted. The residual bones were washed with PBS and immediately put into ISOGEN extraction buffer. Twenty µg and 5 µg of total RNA from bone marrow cells and residual bones, respectively, were run on a 1.2% agarose, 2.2 M formaldehyde gel, transferred to a nitrocellulose membrane by positive pressure, and fixed to the membrane by ultraviolet irradiation. After 1 h of prehybridization in GMC buffer (0.5 M Na2HPO4, 1% bovine serum albumin, 1 mM EDTA, and 7% SDS, pH 7.2) at 60 °C, filters were hybridized overnight in GMC buffer at 65 °C with a random primer [32P]dCTP-labeled cDNA probe for Gas6, Tyro 3, FGF-2, FGFR1, M-CSF, and c-Fms. cDNA probes were generated by RT-PCR using the template of total RNA from mouse brain. The primers for probes were as follows: Gas6, sense (5'-CCATCAACCACGGCATGTGG-3') and antisense (5'-TCGCACACCTTGATTTCCAT-3'); Tyro 3, sense (5'-GGAAGAGACGCAAGGAGAC-3') and antisense (5'-ATGGGAATGGGGAGACGAC-3'); FGF-2, sense (5'-CAAGCAGAAGAGAGAGGAGTTGTGTC-3') and antisense (5'-CAGTTCGTTTCAGTGCCACATACC-3'); FGFR1, sense (5'-TGGAGTTCATGTGCAAGGTG-3') and antisense (5'-ATAGAGAGGACCATCCTGTG-3'); M-CSF, sense (5'-ACAACACCCCCAATGCTAAC-3') and antisense (5'-ACTGCCTGCGTCCTCTATGC-3'); c-Fms, sense (5'-TGCTAAAGTCCACGGCTCAT-3') and antisense (5'-CAGTCCAAAGTCCCCAATCT-3').

Filters were washed in 1× SSC (0.15 M NaCl, 15 mM Na3 citrate, pH 7.0) plus 0.1% SDS twice for 15 min at 65 °C, then once for 15 min in 0.1× SSC plus 0.1% SDS at 65 °C. Signals were quantitated by densitometry (Bio-Rad). Filters were stripped by boiling in 0.1% SDS + 0.1× SSC between hybridizations.

Statistical Analysis-- Means of groups were compared by analysis of variance and significance of differences was determined by post hoc testing using Bonferroni's method.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effects of Gas6 on the Function, Differentiation, and Survival of Osteoclasts-- To examine the effect of Gas6 on the function of mouse osteoclasts, the pit area on a dentine slice resorbed by crude osteoclastic cells formed in the coculture of mouse osteoblasts and bone marrow cells in the presence of 1,25(OH)2 vitamin D3 and PGE2 was measured. Gas6 (>= 10-11 M) dose-dependently stimulated the resorbed pit area up to 2.1-fold of the control culture (Fig. 1, top panel). This stimulation was not due to the increase in the number of osteoclasts but due to the activation of each osteoclast function because the number of TRAP-positive multinucleated osteoclasts on a dentine slice was not affected by Gas6 (Fig. 1, middle panel). In fact, the effect of Gas6 on the pit area per osteoclast (resorbed pit area/osteoclast number in a dentine slice) showed a similar pattern to that on the resorbed pit area (Fig. 1, bottom panel).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Dose response of effects of Gas6 on resorbed pit area (top), osteoclast number (middle), and the pit area per osteoclast (bottom) on a dentine slice. Osteoblasts from neonatal mouse calvariae and bone marrow cells from 8-week-old mice were cocultured on a collagen gel to form osteoclasts. A crude fraction of cells including osteoclasts was then released from the gel and further cultured on a dentine slice with or without Gas6 (10-14-10-8 M). After 48 h of culture, the total pit area and the osteoclast number were measured by toluidine blue and TRAP staining, respectively. Data are expressed as means (bars) ± S.E. (error bars) for 8 cultures/group. *, p < 0.01, significantly different versus control.

To confirm the action of Gas6 on osteoclast differentiation, dose response of effects of Gas6 (10-14 to 10-8 M) on TRAP-positive multinucleated osteoclast formation in the coculture for 6 days on a plastic dish was examined. Gas6 did not increase osteoclast formation at any concentration, whereas FGF-2 and 1,25(OH)2 vitamin D3, positive controls, stimulated it potently (Fig. 2A). Gas6 also did not affect TRAP-positive multinucleated osteoclast formation in the culture of mouse bone marrow cells alone, although FGF-2 and 1,25(OH)2 vitamin D3 did (data not shown).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of Gas6 on the differentiation (A) and the survival (B) of osteoclasts. A, dose response of effects of Gas6, FGF-2, and 1,25(OH)2 D3 (Vit.D3) on TRAP-positive multinucleated cell formation in the coculture system. Mouse bone marrow cells and osteoblasts were cocultured with or without Gas6 (10-14 to 10-8 M), FGF-2 (10-8 M), and 1,25(OH)2 D3 (10-8 M) on plastic dishes for 6 days. TRAP-positive multinucleated cells containing more than three nuclei were counted as osteoclasts. Data are expressed as means (bars) ± S.E. (error bars) for 8 cultures/group. B, effect of Gas6 and M-CSF on the survival of isolated osteoclasts. Mouse osteoclasts isolated from the coculture on a plastic dish were further cultured with or without Gas6 (10-8 M) or M-CSF (100 ng/ml) for various periods up to 72 h. Trypan blue-negative and TRAP-positive osteoclasts were counted as living osteoclasts. Data are expressed as means (symbols) ± S.E. (error bars) for 6 cultures/group. *, p < 0.01, significant difference from control culture at each time point.

We further investigated the effect of Gas6 (10-8 M) on the survival of osteoclasts. Mouse osteoclasts isolated from the coculture were cultured on a plastic dish for up to 72 h with or without Gas6 and M-CSF (100 ng/ml) as a positive control (Fig. 2B). The survival rates decreased similarly with time in the control and Gas6-treated cultures. At 24 h only 32.5% and 22.5% of initially surviving cells still adhered to the dish in control and Gas6-treated cultures, respectively, and by 72 h all cells had died in both cultures. On the contrary, M-CSF increased the survival rate of osteoclasts as reported previously (6-10); the survival rates were 83.3% at 24 h and 17.8% of cells were still alive after 72 h. Hence, these studies using mouse culture systems revealed that Gas6 did not affect the differentiation or survival of osteoclasts, but did stimulate their bone resorptive function.

Expression Pattern of Gas6 and Tyro 3 in Bone Cells-- To study the expression of Gas6 and Tyro 3 in cells of osteoblastic and osteoclastic lineages, mRNA levels in osteoblasts, osteoclasts, spleen cells, bone marrow cells, and brain were examined by RT-PCR. Gas6 was expressed in all cells examined; however, the expression of Tyro 3 was detected only in osteoclasts and brain (Fig. 3A). Western blot analysis confirmed that the protein level of Tyro 3 was detected in osteoclasts, but not in osteoblasts (Fig. 3B). To investigate the expression of Tyro 3 during the differentiation of osteoclastic cells, Tyro 3 mRNA levels were examined in spleen cells cultured in the presence of soluble RANKL/ODF and M-CSF without support of osteoblastic/stromal cells (Fig. 3C). Because we extracted mRNA from cultured spleen cells every day, various differentiation stages of osteoclastic cells were assumed to be included. TRAP-positive multinucleated osteoclasts became detectable at 5 days of culture and increased at 6 days, and Tyro 3 expression was detected slightly at 5 days and abundantly at 6 days of culture. These findings confirm that Tyro 3 is expressed predominantly in mature osteoclasts, but not in osteoclast precursors. We therefore propose that this localization of Tyro 3 may explain the selective action of Gas6 on the function of mature osteoclasts.



View larger version (59K):
[in this window]
[in a new window]
 
Fig. 3.   Expression patterns of Gas6 and Tyro 3 in bone cells. A, messenger RNA levels of Gas6 and Tyro 3 in mouse osteoblasts (OB), osteoclasts (OCL), spleen cells, bone marrow, and brain (RT-PCR). B, protein levels of Tyro 3 in mouse osteoclasts (OCL) and osteoblasts (OB) (Western blotting). C, Tyro 3 mRNA level and TRAP-positive osteoclast formation during differentiation of osteoclastic cells in the mouse spleen cell culture (RT-PCR). Total RNA was extracted from osteoblasts, osteoclasts, spleen cells, bone marrow, and brain as described under "Experimental Procedures." The PCR products for Gas6 and Tyro 3 were 589 and 445 base pairs, respectively. For Western blotting, cellular proteins extracted with TNE buffer were subjected to SDS-PAGE, and immunoblotted with polyclonal anti-goat Tyro 3 antibody or nonimmune IgG. To confirm the specificity of these blottings, stripped membranes were immunoreacted with each polyclonal anti-Tyro 3 and respective blocking peptide. For spleen cell cultures, spleen cells (2 × 108 cells/dish) were cultured in the presence of soluble RANKL/ODF and M-CSF for 6 days, and mRNA was extracted every day. TRAP-positive multinucleated cells containing more than three nuclei were counted as osteoclasts (# of OCL). G3PDH, glyceraldehyde-3-phosphate dehydrogenase.

Intracellular Signaling through Gas6/Tyro 3 in Isolated Osteoclasts-- To learn the mechanism of Gas6/Tyro 3 signaling in mature osteoclasts, we examined the time course of effects of Gas6 (5 × 10-9 M) on tyrosine phosphorylation of cellular proteins in isolated mouse osteoclasts (Fig. 4A). Several proteins were phosphorylated by Gas6 as early as 1 min, and this activation was maintained for 10 min. The c-Src signal was used as an internal control. Western blot analyses using antibodies against specific proteins related to MAPKs revealed that phosphorylation of p42/p44 MAPK was seen at 1 min and maintained for 10 min, while neither p38 nor JNK MAPK phosphorylation was seen (Fig. 4A). To investigate the autophosphorylation of Tyro 3 by Gas6, the kinase activity of immunoprecipitated Tyro 3 was examined by in vitro kinase assay (Fig. 4B). Gas6 induced the kinase activity of Tyro 3 at 1 min, reached maximum at 2 min, and decreased considerably after 5 min.



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 4.   Intracellular signaling through Gas6/Tyro 3 in isolated osteoclasts. A, effects of Gas6 on phosphorylation of cellular proteins and MAPKs in isolated osteoclasts. Mouse osteoclasts isolated from the coculture were cultured with or without Gas6 (5 × 10-9 M) for the indicated period (0-10 min) and lysed with TNE buffer. Twenty µg of cell lysates was subjected to 7.5% SDS-PAGE, and immunoblotted with antibodies against phosphotyrosine, Src, phospho-p44/42 MAPK, phospho-p38 MAPK, and phospho-JNK MAPK. Arrowhead indicates 170-kDa protein (the same size as Tyro 3). B, tyrosine kinase activity of immunoprecipitated Tyro 3 in isolated osteoclasts. Isolated osteoclasts were cultured with and without Gas6 (5 × 10-9 M) for various periods (1-10 min), lysed with TNE buffer, and 100 µg of cell lysates was immunoprecipitated with polyclonal anti-Tyro 3 antibody. The samples were incubated in kinase buffer with [gamma -32P]ATP and subjected to SDS-PAGE. C, effects of PD98059 (PD) and SB203580 (SB) on resorbed pit formation stimulated by Gas6 on a dentine slice. Osteoblasts from neonatal mouse calvariae and bone marrow cells from 8-week-old mice were cocultured on a collagen gel to form osteoclasts. Crude osteoclastic cells released from the coculture on a collagen gel were further cultured on a dentine slice with or without Gas6. Gas6 (10-8 M), PD98059 (1, 3, 10, and 30 µM), and SB203580 (30 µM) were added to the culture at 1 h after the seeding. After 48 h of culture, total pit area in a dentine slice was measured. Data are expressed as means (bars) ± S.E. (error bars) for 8 cultures/group. *, p < 0.01, significant stimulation by Gas6; #, p < 0.01, significant inhibition by PD98059.

To examine the functional relevance of the activation of p42/p44 MAPK by Gas6 in osteoclasts, PD98059, a specific inhibitor of upstream kinase of p42/p44 MAPK (26, 27), was added to the pit formation assay system (Fig. 4C). PD98059 (1-30 µM) dose-dependently inhibited the stimulation of Gas6 on pit formation resorbed by mouse osteoclasts to the levels of the control culture, while SB203580 (30 µM), a specific inhibitor of p38 MAPK (28, 29), did not affect the Gas6 stimulation. Although PD98059 at the highest concentration (30 µM) did not decrease the resorbed pit formation in the control culture, inhibitors of Src kinase, herbimycin (1 µM) and PP1 (10 µM), abrogated pit formation not only in the Gas6-stimulated culture but also in the control culture (data not shown), suggesting the essential role of Src kinase signaling in the basal function of osteoclasts.

Messenger RNA Levels of RTKs and Their Ligands in Bone and Bone Marrow of Sham-operated, OVX, and Estrogen-replaced OVX Mice-- The physiological relevance of this Gas6/Tyro 3 signaling to the pathophysiology of bone loss by estrogen deficiency was investigated by examination of mRNA levels of Gas6 and Tyro 3 in cells of bone marrow and residual long bones of sham-operated, OVX, and estrogen-replaced OVX mice (Fig. 5). Since we assume it possible that signaling through RTKs on osteoclasts may contribute to the pathophysiology of osteopenic disorders, we also examined mRNA levels of other RTKs and their ligands: FGFR1 and FGF-2, and c-Fms & M-CSF, which are known to regulate osteoclast function or survival (5-10). Among them, Gas6 mRNA level in bone marrow cells was up-regulated by OVX and was reduced by estrogen replacement. No Tyro 3 expression could be detected by Northern blotting either in bone or bone marrow of any mice, although it was detected as a single band when mRNA from mouse brain was used (data not shown). Among other RTKs and ligands, M-CSF was up-regulated by OVX as reported previously (21-24), although it was little reduced by estrogen replacement. Messenger RNA levels of other molecules were not regulated by OVX or estrogen replacement. It is therefore proposed that the up-regulation of Gas6 expression in bone marrow may possibly contribute to the bone resorptive status by estrogen deficiency.



View larger version (69K):
[in this window]
[in a new window]
 
Fig. 5.   Messenger RNA levels of RTKs and their ligands in bone and bone marrow of sham-operated (Sham), OVX, and estrogen-replaced OVX (OVX+E) mice. Eight-week-old mice were subjected to either ovariectomy (n = 12) or sham operation (n = 6). The OVX mice were implanted with either placebo pellets (n = 6) or slow release pellets of 17beta -estradiol (n = 6). Mice were sacrificed 3 weeks after surgery, the whole tibiae and femora were excised, and total RNA was extracted from bone marrow and the residual bone as described under "Experimental Procedures." Twenty µg and 5 µg of total RNA from bone marrow and residual bone, respectively, were run on a gel, and mRNA levels of Gas6, Tyro 3, FGF-2, FGFR1, M-CSF, and c-Fms were analyzed by Northern blotting using cDNA probes produced by PCR. The number under each band is the treated/control ratio of the intensity of each band normalized to that of glyceraldehyde-3-phosphate dehydrogenase (G3PDH) measured by densitometry.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This study demonstrated that Gas6, although ubiquitously expressed in bone cells, did not affect the differentiation or survival of osteoclasts, but stimulated osteoclast bone resorptive function using several mouse culture systems. This may be due to the restricted localization of its receptor Tyro 3 on mature osteoclasts. Gas6 was further shown to activate osteoclasts through the phosphorylation of Tyro 3 and p42/p44 MAPK in mature osteoclasts. This Gas6/Tyro 3 signaling in osteoclasts was suggested to be involved in bone loss by estrogen deficiency because Gas6 mRNA level was up-regulated by OVX and reduced by estrogen replacement.

Gas6 is reported to be expressed ubiquitously in heart, lung, stomach, kidney, muscle, brain, spleen, liver, ovary, and testis (30), although little is known about its function in these organs. It is reported to increase the proliferation and the survival of fibroblasts and vascular smooth muscle cells (31, 32). The expression pattern of Tyro 3, on the other hand, is limited to the central nervous system, kidney, ovary, and testis (11-16). The downstream pathway of Gas6/Tyro 3 signaling has been little investigated. The possible mediation by p42/p44 MAPK shown here in osteoclasts has also been reported in a previous study using human embryonic kidney 293 cells (33), while that of phosphatidylinositol 3-kinase pathway is indicated in NIH3T3 cells (34). However, functional or physiological relevance of the signaling through Gas6/Tyro 3 in these cells remains elusive.

FGF-2, M-CSF, and Gas6 are potent regulators of osteoclastic bone resorption whose receptors are RTKs expressed on mature osteoclasts. We recently reported that FGF-2 acts directly on mature osteoclasts through the signaling pathway similar to that of Gas6: activation of its receptor FGFR1 and p42/p44 MAPK (6). M-CSF is reported to activate its receptor, c-Fms, followed by the activation of not only p42/p44 MAPK pathway (10) but also c-Src-dependent pathway (8). c-Src, a ubiquitous cellular tyrosine kinase, which is highly expressed in osteoclasts, is essential for osteoclasts to form a ruffled border and to resorb bone (35), and the contribution of c-Src kinase to Gas6/Tyro 3 signaling has been suggested (36). In this study, inhibitors of the Src family kinases, herbimycin and PP1, abrogated the osteoclast function in control cultures as well as in Gas6-stimulated cultures. Hence, we assume that the Src kinase signal may be essential for the basal osteoclast function, while p42/p44 MAPK is the major pathway for the Gas6 action.

Although the essential component of signaling regulating osteoclast differentiation and function is controversial, the roles of NF-kappa B and JNK have been extensively investigated (37). The stimulation by RANKL/ODF has been demonstrated to be mediated by the activation of NF-kappa B, which is dependent on the interaction with tumor necrosis factor receptor-associated factor 6 (TRAF6) or TRAF2 (38). In fact, knockout mice of both NF-kappa B1 and NF-kappa B2, and of TRAF6 exhibited severe osteopetrosis due to the impaired osteoclast differentiation and function (39, 40). Although RANKL/ODF also activates JNK in osteoclasts (37), the role of osteoclast function is still controversial. In this study, JNK does not seem to mediate the Gas6 effect judging from the lack of JNK phosphorylation by Gas6. The essential signal pathway for the survival of osteoclasts is also controversial. NF-kappa B pathway (9) and p42/p44 MAPK pathway (10) have been reported to be important in sustaining the survival of osteoclasts. In the present study, although Gas6 induced activation of p42/p44 MAPK, it did not promote the survival of osteoclasts. This result, however, cannot rule out possibility of involvement of p42/p44 MAPK in osteoclast survival because the p42/p44 MAPK activation by Gas6 might be insufficient to sustain the survival while sufficient to activate osteoclast function.

In regard to the possible physiological relevance, this study demonstrated that OVX increased and estrogen replacement decreased the Gas6 mRNA expression in bone marrow. OVX animal is a model for the postmenopausal osteoporosis caused by estrogen withdrawal in humans. Joint destruction in RA patients is also accompanied by the acceleration of osteoclastic bone resorption. We recently reported that increased FGF-2 in the synovial fluid contributed to joint destruction through a direct action on mature osteoclasts (20). Expressions of Gas6 and Tyro 3 have been recently demonstrated in the synovium of RA patients (41). These observations suggest that Gas6 as well as FGF-2 play some roles in the pathological bone disorders in these diseases. In addition, Gas6 and FGF-2 have a common action in induction of angiogenesis. Regarding other angiogenic growth factors besides Gas6 and FGF-2, vascular endothelial growth factor has been reported to enhance the osteoclastic bone resorption directly and indirectly in cultures (42-44). In our recent study to identify RTKs expressed on rabbit mature osteoclasts, we cloned an RTK, TIE, whose ligands are angiopoietins, other potent angiogenic growth factors (4). These findings indicate that several angiogenic factors have a common action to stimulate osteoclastic function as well as angiogenesis, suggesting a positive interrelationship between the bone resorption and the invasion of blood vessels during bone modeling and remodeling.

The results in this study demonstrate that Gas6/Tyro 3, an RTK signaling, may play an important role in the mature osteoclast function. This direct action of Gas6 on osteoclasts might possibly have a key function in bone loss by estrogen deficiency. Further studies will reveal the contribution of RTK signalings like Gas6/Tyro 3 to the pathophysiology of osteopenic disorders.


    ACKNOWLEDGEMENT

We thank Dr. C. C. Pilbeam for careful review of this manuscript.


    FOOTNOTES

* This work was supported by Grant-in-aid 12470303 for Scientific Research from the Japanese Ministry of Education, Science, Sports and Culture, a grant from the Uehara Memorial Foundation, and a Bristol-Myers Squibb/Zimmer unrestricted research grant.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed. Tel.: 81-3-3815-5411 (ext. 33376 or 33375); Fax: 81-3-3818-4082; E-mail: kawaguchi-ort@h.u-tokyo.ac.jp.

Published, JBC Papers in Press, November 17, 2000, DOI 10.1074/jbc.M007393200


    ABBREVIATIONS

The abbreviations used are: NF, nuclear factor; RT, reverse transcriptase; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; RA, rheumatoid arthritis; FBS, fetal bovine serum; PBS, phosphate-buffered saline; JNK, c-Jun N-terminal kinase; RANKL/ODF, receptor activator of nuclear factor NF-kappa B ligand/osteoclast differentiation factor; TRAP, tartrate-resistant acid phosphatase; RTK, receptor tyrosine kinase; M-CSF, macrophage colony-stimulating factor; MAPK, mitogen-activated protein kinase; FGF-2, fibroblast growth factor-2; FGFR1, fibroblast growth factor receptor 1; OVX, ovariectomized; alpha MEM, alpha -minimal essential medium.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Cell 93, 165-176[Medline] [Order article via Infotrieve]
2. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuku, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashino, K., Udagawa, N., Takahashi, N., and Suda, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3597-3602[Abstract/Free Full Text]
3. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. (1999) Nature 397, 315-323[CrossRef][Medline] [Order article via Infotrieve]
4. Nakamura, Y. S., Hakeda, Y., Takekura, N., Kameda, T., Hamaguchi, I., Miyamoto, T., Kakudo, S., Nakano, T., Kumegawa, M., and Suda, T. (1998) Stem Cells 18, 229-238
5. Kawaguchi, H., Chikazu, D., Nakamura, K., Kumegawa, M., and Hakeda, Y. (2000) J. Bone Miner. Res. 15, 466-473[Medline] [Order article via Infotrieve]
6. Chikazu, D., Hakeda, Y., Ogata, N., Nemoto, K., Itabashi, A., Takato, T., Kumegawa, M., Nakamura, K., and Kawaguchi, H. (2000) J. Biol. Chem. 275, 31444-31450[Abstract/Free Full Text]
7. Fuller, K, Owens, J. M., Jagger, C. J., Wilson, A., Moss, R., and Chambers, T. J. (1993) J. Exp. Med. 178, 1733-1744[Abstract]
8. Insogna, K. L., Sahni, M., Grey, A. B., Tanaka, S., Horne, W. C., Neff, L., Mitnick, M., Levy, J. B., and Baron, R. (1997) J. Clin. Invest. 100, 2476-2485[Abstract/Free Full Text]
9. Jimi, E., Nakamura, I., Ikebe, T., Akiyama, S., Takahashi, N., and Suda, T. (1998) J. Biol. Chem. 273, 8799-8805[Abstract/Free Full Text]
10. Miyazaki, T., Katagiri, H., Kanegae, Y., Takayanagi, H., Sawada, Y., Yamamoto, A., Pando, M. P., Asano, T., Verma, I. M., Oda, H., Nakamura, K., and Tanaka, S. (2000) J. Cell Biol. 148, 333-342[Abstract/Free Full Text]
11. Ohashi, K., Mizuno, K., Kuma, K., Miyata, T., and Nakamura, T. (1994) Oncogene 9, 699-705[Medline] [Order article via Infotrieve]
12. Mark, M. R., Scadden, D. T., Wang, Z., Gu, Q., Goddard, A., and Godowski, P. J. (1994) J. Biol. Chem. 269, 10720-10728[Abstract/Free Full Text]
13. Fujimoto, J., and Yamamoto, T. (1994) Oncogene 9, 693-698[Medline] [Order article via Infotrieve]
14. Dai, W., Pan, H., and Hassanain, H. (1994) Oncogene 9, 975-979[Medline] [Order article via Infotrieve]
15. Lai, C., Gore, M., and Lemle, G. (1994) Oncogene 9, 2567-2578[Medline] [Order article via Infotrieve]
16. Schulz, N. T., Paulhiac, C. I., and Lee, L. (1995) Mol. Brain Res. 28, 273-280[CrossRef][Medline] [Order article via Infotrieve]
17. Varnum, B. C., Young, C., Elliott, G., Garcia, A., Bartley, T. D., Fridell, Y.-W., Hunt, R. W., Trail, G., Clogston, C., Toso, R. J., Yanagihara, D., Bennett, L., Sylber, M., Merewether, L. A., Tseng, A., Escober, E., Liu, E. T., and Yamane, H. K. (1995) Nature 373, 623-626[CrossRef][Medline] [Order article via Infotrieve]
18. Stitt, T. N., Conn, G., Gore, M., Lai, C., Bruno, J., Radiziejewski, C., Mattsson, K., Fisher, J., Gies, D. R., Jones, P. F., Masiakowski, P., Ryan, T. E., Tobkes, N. J., Chen, D. H., Distefano, P. S., Long, G. L., Basilico, C., Goldfarb, M. P., Lemke, G., Glass, D. J., and Yancopoulos, G. D. (1995) Cell 80, 661-670[Medline] [Order article via Infotrieve]
19. Nakano, T., Higashino, K., Kikuchi, N., Kishino, J., Nomura, K., Fujita, H., Ohara, O., and Arita, H. (1995) J. Biol. Chem. 270, 5702-5705[Abstract/Free Full Text]
20. Manabe, N., Oda, H., Nakamura, K., Kuga, Y., Uchida, S., and Kawaguchi, H. (2000) Rheumatology 38, 714-720[Abstract/Free Full Text]
21. Kimble, R. B., Srivastava, S., Ross, F. P., Matayoshi, A., and Pacifici, R. (1996) J. Biol. Chem. 271, 28890-28897[Abstract/Free Full Text]
22. Srivastava, S., Weitzmann, M. N., Kimble, R. B., Rizzo, M., Zahner, M., Milbrandt, J., Ross, F. P., and Pacifici, R. (1998) J. Clin. Invest. 102, 1850-1859[Abstract/Free Full Text]
23. Lea, C. K., Sarma, U., and Flanagan, A. M. (1999) Endocrinology 140, 273-279[Abstract/Free Full Text]
24. Cenci, S., Weitzmann, M. N., Gentile, M. A., Aisa, M. C., and Pacifici, R. (2000) J. Clin. Invest. 105, 1279-1287[Abstract/Free Full Text]
25. Zimmermann, M. (1983) Pain 16, 109-110[CrossRef][Medline] [Order article via Infotrieve]
26. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 27489-27494[Abstract/Free Full Text]
27. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7686-7689[Abstract]
28. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739-746[CrossRef][Medline] [Order article via Infotrieve]
29. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. (1995) FEBS Lett. 364, 229-233[CrossRef][Medline] [Order article via Infotrieve]
30. Manfioletti, G., Brancolini, C., Avanzi, G., and Schneider, C. (1993) Mol. Cell. Biol. 13, 4976-4985[Abstract]
31. Goruppi, S., Ruaro, E., and Schneider, C. (1996) Oncogene 12, 471-480[Medline] [Order article via Infotrieve]
32. Nakano, T., Kawamoto, K., Higashino, K., and Arita, H. (1996) FEBS Lett. 387, 78-80[CrossRef][Medline] [Order article via Infotrieve]
33. Chen, J., Carey, K., and Godowski, P. J. (1997) Oncogene 14, 2033-2039[CrossRef][Medline] [Order article via Infotrieve]
34. Lan, Z., Wu, H., Li, W., Wu, S., Lu, L., Xu, M., and Dai, W. (2000) Blood 95, 633-638[Abstract/Free Full Text]
35. Boyce, B. F., Yoneda, T., Lowe, C., Soriano, P., and Mundy, G. R. (1992) J. Clin. Invest. 90, 1622-1627[Medline] [Order article via Infotrieve]
36. Toshima, J., Ohashi, K., Iwashita, S., and Mizuno, K. (1995) Biochem. Biophys. Res. Commun. 209, 656-663[CrossRef][Medline] [Order article via Infotrieve]
37. Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., and Suda, T. (1999) J. Immunol. 163, 434-442[Abstract/Free Full Text]
38. Galibert, L., Tometsko, M. E., Anderson, D. M., Cosman, D., and Dougall, W. C. (1998) J. Biol. Chem. 273, 34120-34127[Abstract/Free Full Text]
39. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., and Bravo, R. (1997) Nat. Med. 3, 1285-1289[Medline] [Order article via Infotrieve]
40. Lomaga, M. A., Yeh, W. C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., van der Heiden, A., Itie, A., Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J. M., Paige, C. J., Lacey, D. L., Dunstan, C. R., Boyle, W. J., Goeddel, D. V., and Mak, T. W. (1999) Genes Dev. 13, 1015-1024[Abstract/Free Full Text]
41. O'Donnell, K., Harkes, I. C., Dougherty, L., and Wicks, I. P. (1999) Am. J. Pathol. 154, 1171-1180[Abstract/Free Full Text]
42. Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., and Ferrara, N. (1999) Nat. Med. 5, 623-628[CrossRef][Medline] [Order article via Infotrieve]
43. Niida, S., Kaku, M., Amano, H., Yoshida, H., Kataoka, H., Nishikawa, S., Tanne, K., Maeda, N., Nishikawa, S., and Kodama, H. (1999) J. Exp. Med. 190, 293-298[Abstract/Free Full Text]
44. Nakagawa, M., Kaneda, T., Arakawa, T., Morita, S., Sato, T., Yomada, T., Hanada, K., Kumegawa, M., and Hakeda, Y. (2000) FEBS Lett. 473, 161-164[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.